Clinical trial
A Multicentre, International, Randomised, Double-blind, Placebo-controlled Study to Demonstrate the Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
NCT03724240 is registered in ClinicalTrials.gov with ASIT Biotech S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, International, Randomised, Double-blind, Placebo-controlled Study to Demonstrate the Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
- Lead sponsor
- ASIT Biotech S.A.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 2, 2019
- Completion date
- December 31, 2019
- Enrollment
- 624 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hay fever